European Heart Journal Advance Access published online on December 6, 2004
European Heart Journal, doi:10.1093/eurheartj/ehi057
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Cardiology B, The Heart Center, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark
* To whom correspondence should be addressed. Aims To evaluate the prognostic importance of pre-discharge maximal symptom-limited exercise testing (ET) following acute myocardial infarction (AMI) in the era of aggressive reperfusion. Methods and results In the DANAMI-2 (the second DANish trial in AMI) study, patients with ST-elevation AMI (STEMI) were randomized to primary angioplasty (PCI) or fibrinolysis. Of 1462 patients discharged alive, 1164 (79.6%) performed an ET. Primary endpoint was a composite of death and re-infarction. Patients randomized to fibrinolysis developed ST-depression to a greater extent than patients randomized to primary PCI (21.7 vs. 15.3%, P = 0.007). Multivariable predictors of death and re-infarction included age, gender, diabetes, previous stroke, anterior AMI, randomization to fibrinolysis, and exercise capacity [risk ratio (RR) 0.82 (0.72-0.93); P < 0.001]. ST-depression was predictive of the clinical outcome [RR 1.57 (1.00-2.48); P < 0.05] in multivariable analysis, but stratified according to treatment groups there was a significant association between ST-depression and outcome in the fibrinolysis group [RR 1.95 (1.11-3.44); P < 0.05], but not in the primary PCI group [RR 1.06 (0.47-2.36); P = ns]. However, the P-value for interaction was 0.15. Conclusion Exercise testing after contemporary reperfusion therapies for STEMI confers important prognostic information. Exercise capacity is a strong prognostic predictor of death and re-infarction irrespective of treatment strategy, whereas the prognostic significance of ST-depression seems to be strongest in the fibrinolysis-treated patients.
Clinical research
The prognostic value of pre-discharge exercise testing after myocardial infarction treated with either primary PCI or fibrinolysis: a DANAMI-2 sub-study
Nana Valeur, E-mail: nvaleur{at}dadlnet.dk
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74. [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J., January 1, 2007; 28(1): 88 - 136. [Full Text] [PDF] |
||||
![]() |
M. Bartnik, K. Malmberg, and L. Ryden Management of patients with type 2 diabetes after acute coronary syndromes Diabetes and Vascular Disease Research, October 1, 2005; 2(3): 144 - 154. [Abstract] [PDF] |
||||
![]() |
M. Borjesson and M. Dellborg Exercise testing post-MI: still worthwhile in the interventional era Eur. Heart J., January 2, 2005; 26(2): 105 - 106. [Full Text] [PDF] |
||||


